Glucocorticoid receptor in health and disease

Journal of Medical Biochemistry

Volumn 28, Issue 4, 2009, Pages 248-261

  Dunderski, Jadranka ^a   Matić, Gordana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Antiinflammatory drugs; Glucocorticoid hormones; Glucocorticoid receptor; Mechanism of action; Pathogenesis of disease

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; 4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; A 276575; ARGIPRESSIN; CORTICOSTEROID; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; DNA; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; HYDROCORTISONE; HYDROCORTISONE DERIVATIVE; LIPOSOME; NCX 1004; NCX 1015; NITRIC OXIDE; PRASTERONE SULFATE; PREDNISOLONE; PREDNISOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BLOOD BRAIN BARRIER; BONE DISEASE; DNA POLYMORPHISM; DRUG EFFICACY; ENTERITIS; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; GRAFT REJECTION; HODGKIN DISEASE; HOMEOSTASIS; HORMONE METABOLISM; HORMONE RELEASE; HORMONE RESISTANCE; HORMONE STRUCTURE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LEUKEMIA; OVARY POLYCYSTIC DISEASE; POSTTRAUMATIC STRESS DISORDER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SUSTAINED DRUG RELEASE;

EID: 70449370157     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-009-0022-y     Document Type: Review

References (111)

1. Sapolsky RM, Romero LM, Munck AU. How do gluco - corticoids influence stress responses? Integrating permis - sive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000; 21: 55-89.
2. Munck A, Naray-Fejes-Toth A. The ups and downs of glucocorticoid physiology. Permissive and suppressive effects revisited. Mol Cell Endocrinol 1992; 90: C1-4.
3. Buckingham JC. Glucocorticoids: Exemplars of multitasking. Br J Pharmacol 2006; 147 Suppl. 1: S258-68.
4. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998; 19: 269-301.
5. De Kloet ER, Karst H, Joels M. Corticosteroid hormones in the central stress response: quick-and-slow. Front Neuro endocrinol 2008; 29: 268-272
6. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: An update. Pharmacol Rev 1998; 50: 515-596
7. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006; 148: 245-254
8. Schoneveld OJ, Gaemers IC, Lamers WH. Mechanisms of glucocorticoid signalling. Biochim Biophys Acta 2004; 1680: 114-128
9. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, et al. Crystal structure of the gluco corti - coid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recogni - tion. Cell 2002; 110: 93-105.
10. Kauppi B, Jakob C, Farnegardh M, Yang J, Ahola H, Alarcon M, et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 2003; 278: 22748-22754
11. Yudt MR, Jewell CM, Bienstock RJ, Cidlowski JA. Molecular origins for the dominant negative function of human glucocorticoid receptor beta. Mol Cell Biol 2003; 23: 4319-4330
12. Bourguet W, Germain P, Gronemeyer H. Nuclear receptor ligand-binding domains: Three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 2000; 21: 381-388
13. Rosenfeld MG, Glass CK. Coregulator codes of transcrip - tional regulation by nuclear receptors. J Biol Chem 2001; 276: 36865-36868
14. Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, Sigler PB. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 1991; 352: 497-505.
15. Ford J, McEwan IJ, Wright AP, Gustafsson JA. Invol - vement of the transcription factor IID protein complex in gene activation by the N-terminal transactivation domain of the glucocorticoid receptor in vitro. Mol Endocrinol 1997;11:1467-1475
16. Adcock IM, Ito K. Molecular mechanisms of corticosteroid actions. Monaldi Arch Chest Dis 2000; 55: 256-266
17. Morishima Y, Murphy PJ, Li DP, Sanchez ER, Pratt WB. Stepwise assembly of a glucocorticoid receptor.hsp90 heterocomplex resolves two sequential ATP-dependent events involving first hsp70 and then hsp90 in opening of the steroid binding pocket. J Biol Chem 2000; 275: 18054-18060
18. Morishima Y, Kanelakis KC, Murphy PJ, Shewach DS, Pratt WB. Evidence for iterative ratcheting of receptorbound hsp70 between its ATP and ADP conformations during assembly of glucocorticoid receptor.hsp90 heterocomplexes. Biochemistry 2001; 40: 1109-1116
19. Krstić MD, Rogatsky I, Yamamoto KR, Garabedian MJ. Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor. Mol Cell Biol 1997; 17: 3947-3954
20. Webster JC, Jewell CM, Bodwell JE, Munck A, Sar M, Cidlowski JA. Mouse glucocorticoid receptor phosphory - la tion status influences multiple functions of the receptor protein. J Biol Chem 1997; 272: 9287-9293
21. Wang Z, Frederick J, Garabedian MJ. Deciphering the phosphorylation »code« of the glucocorticoid receptor in vivo. J Biol Chem 2002; 277: 26573-26580
22. Nordeen SK, Suh BJ, Kuhnel B, Hutchison CA, 3rd. Structural determinants of a glucocorticoid receptor recognition element. Mol Endocrinol 1990; 4: 1866-1873
23. La Baer J, Yamamoto KR. Analysis of the DNA-binding affinity, sequence specificity and context dependence of the glucocorticoid receptor zinc finger region. J Mol Biol 1994; 239: 664-688
24. Dahlman-Wright K, Wright A, Gustafsson JA, Carlstedt- Duke J. Interaction of the glucocorticoid receptor DNAbinding domain with DNA as a dimer is mediated by a short segment of five amino acids. J Biol Chem 1991; 266: 3107-3112
25. Schoneveld OJ, Gaemers IC, Das AT, Hoogenkamp M, Renes J, Ruijter JM, Lamers WH. Structural requirements of the glucocorticoid-response unit of the carbamoylphosphate synthase gene. Biochem J 2004; 382: 463-470
26. Truss M, Beato M. Steroid hormone receptors: Inter - action with deoxyribonucleic acid and transcription fac - tors. Endocr Rev 1993; 14: 459-479
27. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997; 387: 733-736
28. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, et al. A CBP integrator complex mediates transcrip - tional activation and AP-1 inhibition by nuclear receptors. Cell 1996; 85: 403-414
29. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996; 382: 319-324
30. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996; 87: 953-959
31. Vo N, Goodman RH. CREB-binding protein and p300 in transcriptional regulation. J Biol Chem 2001; 276: 13505-13508
32. Adcock IM, Caramori G. Cross-talk between proinflammatory transcription factors and glucocorticoids. Immunol Cell Biol 2001; 79: 376-384
33. Wargnier A, Lafaurie C, Legros-Maida S, Bourge JF, Sigaux F, Sasportes M, Paul P. Down-regulation of human granzyme B expression by glucocorticoids. Dexametha - so ne inhibits binding to the Ikaros and AP-1 regulatory elements of the granzyme B promoter. J Biol Chem 1998; 273: 35326-35331
34. Sheppard KA, Phelps KM, Williams AJ, Thanos D, Glass CK, Rosenfeld MG, et al. Nuclear integration of gluco - corticoid receptor and nuclear factor kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem 1998; 273: 29291-29294
35. McKay LI, Cidlowski JA. CBP (CREB binding protein) integrates NF-kappaB (nuclear factor-kappaB) and glucocorticoid receptor physical interactions and antagonism. Mol Endocrinol 2000; 14: 1222-1234
36. Deroo BJ, Archer TK. Glucocorticoid receptor activation of the I kappa B alpha promoter within chromatin. Mol Biol Cell 2001; 12: 3365-3374
37. Adams M, Meijer OC, Wang J, Bhargava A, Pearce D. Homodimerization of the glucocorticoid receptor is not essential for response element binding: Activation of the phenylethanolamine N-methyltransferase gene by dimerization-defective mutants. Mol Endocrinol 2003; 17: 2583-2592
38. Rogatsky I, Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq CM, et al. Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proc Natl Acad Sci U S A 2003; 100: 13845-13850
39. McMaster A, Ray DW. Modelling the glucocorticoid receptor and producing therapeutic agents with antiinflammatory effects but reduced side-effects. Exp Physiol 2007; 92: 299-309.
40. Mohler ML, He YL, Wu ZZ, Hong SS, Miller DD. Dissociated non-steroidal glucocorticoids: Tuning out untoward effects. Expert Opinion on Therapeutic Patents 2007; 17: 37-58.
41. Schacke H, Rehwinkel H, Asadullah K. Dissociated glucocorticoid receptor ligands: Compounds with an improved therapeutic index. Curr Opin Investig Drugs 2005; 6: 503-507
42. Schulz M, Eggert M. Novel ligands: Fine tuning the transcriptional activity of the glucocorticoid receptor. Curr Pharm Des 2004; 10: 2817-2826
43. Teshima M, Fumoto S, Nishida K, Nakamura J, Ohyama K, Nakamura T, et al. Prolonged blood concentration of prednisolone after intravenous injection of liposomal palmitoyl prednisolone. J Control Release 2006; 112: 320-328
44. Perretti M, Paul-Clark MJ, Mancini L, Flower RJ. Gene - ration of innovative anti-inflammatory and anti-arthritic glucocorticoid derivatives that release NO: The nitrosteroids. Dig Liver Dis 2003; 35 Suppl. 2: S41-8.
45. Paul-Clark MJ, Roviezzo F, Flower RJ, Cirino G, Soldato PD, Adcock IM, Perretti M. Glucocorticoid receptor nitration leads to enhanced antiinflammatory effects of novel steroid ligands. J Immunol 2003; 171: 3245-3252
46. Schacke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): Novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007; 275: 109-117
47. Lin CW, Nakane M, Stashko M, Falls D, Kuk J, Miller L, et al. Trans-activation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5- dihydro-9-hydroxy-10-methoxy-2,2,4- trimethyl-5-(1- methylcyclohexen-3-y 1)-1H-[1]benzopyrano[3,4-f]qui - no line (A276575) and its four stereoisomers. Mol Pharmacol 2002; 62: 297-303.
48. Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A 2004; 101: 227-232
49. De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W, Hennuyer N, Hapgood J, et al. A fully dissociated compound of plant origin for inflammatory gene re pres - sion. Proc Natl Acad Sci U S A 2005; 102: 15827-15832
50. Young JD, Lawrence AJ, MacLean AG, Leung BP, McInnes IB, Canas B, et al. Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med 1999; 5: 1424-1427
51. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 2001; 20: 7108-7116
52. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 23-43.
53. Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209-1217
54. Felice MS, Zubizarreta PA, Alfaro EM, Sackmann-Muriel F. Childhood acute lymphoblastic leukemia: Prognostic value of initial peripheral blast count in good responders to prednisone. J Pediatr Hematol Oncol 2001; 23: 411-415
55. Meijer OC, Karssen AM, De Kloet ER. Cell- and tIssuespe cific effects of corticosteroids in relation to gluco cor - ticoid resistance: Examples from the brain. J Endocrinol 2003; 178: 13-18
56. Edwards CR, Benediktsson R, Lindsay RS, Seckl JR. 11 beta-Hydroxysteroid dehydrogenases: Key enzymes in determining tissuespecific glucocorticoid effects. Steroids 1996; 61: 263-269
57. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, et al. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 2003;34:434-439
58. Vanderbilt JN, Miesfeld R, Maler BA, Yamamoto KR. Intracellular receptor concentration limits glucocorticoiddependent enhancer activity. Mol Endocrinol 1987; 1: 68-74.
59. Alarid ET. Lives and times of nuclear receptors. Mol Endocrinol 2006; 20: 1972-1981
60. Hoeck W, Rusconi S, Groner B. Down-regulation and phosphorylation of glucocorticoid receptors in cultured cells. Investigations with a monospecific antiserum against a bacterially expressed receptor fragment. J Biol Chem 1989; 264:14396-14402
61. Silva CM, Powell-Oliver FE, Jewell CM, Sar M, Allgood VE, Cidlowski JA. Regulation of the human gluco corti - coid receptor by long-term and chronic treatment with glucocorticoid. Steroids 1994; 59: 436-442
62. Vedeckis WV, Ali M, Allen HR. Regulation of glucocor - ticoid receptor protein and mRNA levels. Cancer Res 1989; 49: 2295s-302s.
63. Denton RR, Eisen LP, Elsasser MS, Harmon JM. Differential autoregulation of glucocorticoid receptor expression in human T- and B-cell lines. Endocrinology 1993; 133: 248-256
64. Schmidt S, Irving JA, Minto L, Matheson E, Nicholson L, Ploner A, et al. Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor. FASEB J 2006; 20: 2600-2602
65. Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol 2009; 300: 7-16.
66. Lu NZ, Cidlowski JA. Translational regulatory mecha - nisms generate N-terminal glucocorticoid receptor iso - forms with unique transcriptional target genes. Mol Cell 2005; 18: 331-342
67. Turner JD, Schote AB, Keipes M, Muller CP. A new transcript splice variant of the human glucocorticoid receptor: Identification and tissue distribution of hGR Delta 313-338, an alternative exon 2 transactivation do - main isoform. Ann N Y Acad Sci 2007; 1095: 334-341
68. Yudt MR, Cidlowski JA. Molecular identification and characterization of a and b forms of the glucocorticoid receptor. Mol Endocrinol 2001; 15: 1093-1103
69. Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985; 318: 635-641 (Pubitemid 16172412)
70. Oakley RH, Sar M, Cidlowski JA. The human glucoc or - ticoid receptor beta isoform. Expression, biochemical properties, and putative function. J Biol Chem 1996; 271: 9550-9559
71. Presul E, Schmidt S, Kofler R, Helmberg A. Identification, tissue expression, and glucocorticoid responsiveness of alternative first exons of the human glucocorticoid receptor. J Mol Endocrinol 2007; 38: 79-90.
72. Turner JD, Muller CP. Structure of the glucocorticoid receptor (NR3C1) gene 5' untranslated region: Identifi - cation, and tissue distribution of multiple new human exon 1. J Mol Endocrinol 2005; 35: 283-292
73. Russcher H, Dalm VA, De Jong FH, Brinkmann AO, Hofland LJ, Lamberts SW, Koper JW. Associations be - tween promoter usage and alternative splicing of the glucocorticoid receptor gene. J Mol Endocrinol 2007; 38: 91-98
74. Pedersen KB, Geng CD, Vedeckis WV. Three mecha - nisms are involved in glucocorticoid receptor auto re - gulation in a human T-lymphoblast cell line. Biochemistry 2004; 43: 10851-10858
75. Encio IJ, Detera-Wadleigh SD. The genomic structure of the human glucocorticoid receptor. J Biol Chem 1991; 266: 7182-7188
76. Pujols L, Mullol J, Roca-Ferrer J, Torrego A, Xaubet A, Cidlowski JA, Picado C. Expression of glucocorticoid receptor alpha- and beta-isoforms in human cells and tissues. Am J Physiol Cell Physiol 2002; 283: C1324-31.
77. Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, Cid - lowski JA. The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem 1999; 274: 27857-27866
78. Koga Y, Matsuzaki A, Suminoe A, Hattori H, Kanemitsu S, Hara T. Differential mRNA expression of glucocorti - coid receptor alpha and beta is associated with glucocorticoid sensitivity of acute lympho blastic leukemia in children. Pediatr Blood Cancer 2005; 45: 121-127
79. Lewis-Tuffin LJ, Jewell CM, Bienstock RJ, Collins JB, Cidlowski JA. Human glucocorticoid receptor beta binds RU-486 and is transcriptionally active. Mol Cell Biol 2007; 27: 2266-2282
80. Rivers C, Levy A, Hancock J, Lightman S, Norman M. Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing. J Clin Endocrinol Metab 1999; 84: 4283-4286
81. Haarman EG, Kaspers GJ, Pieters R, Rottier MM, Veerman AJ. Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia. Leukemia 2004; 18: 530-537
82. Moalli PA, Pillay S, Krett NL, Rosen ST. Alternatively spliced glucocorticoid receptor messenger RNAs in glucocorticoid-resistant human multiple myeloma cells. Cancer Res 1993; 53: 3877-3879
83. De Lange P, Segeren CM, Koper JW, Wiemer E, Sonneveld P, Brinkmann AO, et al. Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptormediated effects in transfected cells. Cancer Res 2001; 61: 3937-3941
84. Hillmann AG, Ramdas J, Multanen K, Norman MR, Harmon JM. Glucocorticoid receptor gene mutations in leukemic cells acquired in vitro and in vivo. Cancer Res 2000; 60: 2056-2062
85. Irving JA, Minto L, Bailey S, Hall AG. Loss of heterozygosity and somatic mutations of the glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course. Cancer Res 2005; 65: 9712-9718
86. Van Rossum EF, Koper JW, Huizenga NA, Uitterlinden AG, Janssen JA, Brinkmann AO, et al. A polymorphism in the glucocorticoid receptor gene, which decreases sensi - tivity to glucocorticoids in vivo, is associated with low insu lin and cholesterol levels. Diabetes 2002; 51: 3128-3134
87. Russcher H, Smit P, Van Den Akker EL, Van Rossum EF, Brinkmann AO, De Jong FH, et al. Two polymorphisms in the glucocorticoid receptor gene directly affect glucocor - ticoid-regulated gene expression. J Clin Endocrinol Me - tab 2005; 90: 5804-5810
88. Russcher H, Van Rossum EF, De Jong FH, Brinkmann AO, Lamberts SW, Koper JW. Increased expression of the glucocorticoid receptor-A translational isoform as a result of the ER22/23EK polymorphism. Mol Endocrinol 2005; 19: 1687-1696
89. Syed AA, Irving JA, Redfern CP, Hall AG, Unwin NC, White M, et al. Association of glucocorticoid receptor polymorphism A3669G in exon 9beta with reduced central adiposity in women. Obesity (Silver Spring) 2006; 14: 759-764
90. Van Rossum EF, Koper JW, Van Den Beld AW, Uitterlinden AG, Arp P, Ester W, et al. Identification of the BclI polymorphism in the glucocorticoid receptor gene: Association with sensitivity to glucocorticoids in vivo and body mass index. Clin Endocrinol (Oxf) 2003; 59: 585-592
91. Lin RC, Wang XL, Dalziel B, Caterson ID, Morris BJ. Association of obesity, but not diabetes or hypertension, with glucocorticoid receptor N363S variant. Obes Res 2003; 11: 802-808
92. Jewell CM, Cidlowski JA. Molecular evidence for a link between the N363S glucocorticoid receptor polymor - phism and altered gene expression. J Clin Endocrinol Metab 2007; 92: 3268-3277
93. Van Rossum EF, Lamberts SW. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res 2004; 59: 333-357
94. Kojika S, Sugita K, Inukai T, Saito M, Iijima K, Tezuka T, et al. Mechanisms of glucocorticoid resistance in human leukemic cells: Implication of abnormal 90 and 70 kDa heat shock proteins. Leukemia 1996; 10: 994-999
95. Qian X, Zhu Y, Xu W, Lin Y. Glucocorticoid receptor and heat shock protein 90 in peripheral blood mononuclear cells from asthmatics. Chin Med J (Engl) 2001; 114: 1051-1054
96. Matysiak M, Makosa B, Walczak A, Selmaj K. Patients with multiple sclerosis resisted to glucocorticoid therapy: Ab - normal expression of heat shock protein 90 in gluco cor - ticoid receptor complex. Mult Scler 2008; 14: 919-926
97. Ouyang J, Jiang T, Tan M, Cui Y, Li X. Abnormal expression and distribution of heat shock protein 90: Potential etiologic immunoendocrine mechanism of glucocorticoid resistance in idiopathic nephrotic syn - drome. Clin Vaccine Immunol 2006; 13: 496-500.
98. Scammell JG, Denny WB, Valentine DL, Smith DF. Overexpression of the FK506-binding immunophilin FKBP51 is the common cause of glucocorticoid resi - stance in three New World primates. Gen Comp Endo - crinol 2001; 124: 152-165
99. Westberry JM, Sadosky PW, Hubler TR, Gross KL, Scammell JG. Glucocorticoid resistance in squirrel monkeys results from a combination of a transcriptionally incompetent glucocorticoid receptor and overexpression of the glucocorticoid receptor co-chaperone FKBP51. J Steroid Biochem Mol Biol 2006; 100: 34-41.
100. Denny WB, Prapapanich V, Smith DF, Scammell JG. Structure-function analysis of squirrel monkey FK506- binding protein 51, a potent inhibitor of glucocorticoid receptor activity. Endocrinology 2005; 146: 3194-3201
101. Gladkevich A, Kauffman HF, Korf J. Lymphocytes as a neural probe: Potential for studying psychiatric disor - ders. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 559-576
102. Perići ć T Sre ćkovi ć M Mati ć G. Modulation of glucocorticoid receptor function and expression in adolescent moderate asthma. Respiration 2009; 77: 70-75
103. Perićić T Srećković M Matić G. Possible Role of a Hydro gen Peroxide-Mediated Mechanism in Glucocor - ticoid Receptor Functional Alterations Associated with Moderate Asthma. Archives of Biological Sciences 2008; 60: 531-539
104. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-2749
105. Diamanti-Kandarakis E. Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implica - tions. Expert Rev Mol Med 2008; 10: E3.
106. Macut D, Panidis D, Glićić B, Spanos N, Petakov M, Bjekić J, et al. Lipid and lipoprotein profile in women with polycystic ovary syndrome. Can J Physiol Pharma - col 2008; 86: 199-204.
107. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cava - gnini F, Chrousos GP, et al. Diagnosis and complications of Cushing's syndrome: A consensus statement. J Clin Endocrinol Metab 2003; 88: 5593-5602
108. Walker BR, Phillips DI, Noon JP, Panarelli M, Andrew R, Edwards HV, et al. Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 1998; 31: 891-895
109. Shakhov Yu A, Petrichenko IE, Chepurnenko NV, Perova NV, Oganov RG. Reduced sensitivity of peripheral cells to glucocorticoids in hypercholesterolemia. Biochem Int 1989; 18: 913-922
110. Elaković I, Perićić T, Canković- Kadijević M, Matić G. Corre lation between glucocorticoid receptor binding parameters, blood pressure, and body mass index in a healthy human population. Cell Biochem Funct 2007; 25: 427-431
111. Phuc Le P, Friedman JR, Schug J, Brestelli JE, Parker JB, Bochkis IM, Kaestner KH. Glucocorticoid receptordependent gene regulatory networks. PLoS Genet 2005; 1: E16.